Celebration of Faculty Excellence honors Department members
Honors include a Distinguished Faculty award, a newly endowed chair and Distinguished University Scholar.
The recent Celebration of Faculty Excellence honored several members of the University of Louisville Department of Medicine.
"Great people do great things," Jesse Roman, M.D., Chairman of the University of Louisville Department of Medicine said. "When they do, we should reward them, honor them; they and others like them represent the core of academia."
Those from the department who were honored include:
President's Distinguished Faculty Awards
(Award winners receive a medallion and a check for $1,000. They will be featured on campus banners later this year.)
Outstanding Scholarship, Research & Creative Activity: Basic and Applied Sciences
McClain is a widely recognized expert in alcohol-induced organ injury, nutrition and cytokine research and environmental liver injury. He was the first to describe increased inflammatory mediators (cytokines) in alcoholic liver disease and he has made many seminal observations on liver metabolism and nutrition.
A Distinguished University Scholar and associate vice president for translational research, McClain has had continuous primary investigator federal funding for his research since 1977 and is funded by the Veteran's Administration, multiple National Institutes of Health grants and the Department of Defense.
New Endowed Faculty
Abell was one of the founding members of the National Institutes of Health Gastroparesis Clinical Research Symposium, which is entering its seventh year of funding and holds a site at UofL. Since arriving at U of L in 2012, he has set up the Gastrointestinal Motility Clinic at Jewish Hospital/Kentucky One in partnership with the university and University of Louisville Physicians. This program follows approximately 10 percent of the world’s gastrointestinal neurostimulator patients and implants more than 80 percent of the world’s endoscopic devices.
Abell holds the Arthur M. Schoen, M.D., Chair in Gastroenterology in Memory of his Wife, Elizabeth Clark Gentry Schoen and Anna Lee Gentry Brown.
(The goal of the University Scholar and Distinguished Scholar Program is to recruit new faculty scholars and retain existing faculty members who demonstrate superior creativity and scholarship in their field of expertise. Since the program began in 1995, U of L has awarded 105 University and Distinguished University Scholars. Scholars are nominated by their deans, reviewed and recommended by a faculty committee and approved by the president. The Office of the Executive Vice President for Research and Innovation administers the program)
Distinguished University Scholar
Srivastava is in the Division of Cardiovascular Medicine. He has published more than 80 research articles in top-tier scientific journals and has received four major grants from the National Institutes of Health in the past 10 years.
In recognition of his outstanding contribution to cardiovascular research, Srivastava was inducted as a Fellow of American Heart Association in 2010.
(A patent is a grant made by a government that confers upon the creator of an invention the sole right to make, use and sell that invention for a set period of time. It protects the "concept" or "idea" behind the invention.)
Identified and isolated a subpopulation of bone marrow-derived mesenchymal stem cells for use in tissue repair and regeneration that is expected to significantly improve the efficiency of stem cell-mediated cardiac repair.
Confirmed the role of specific enzymes in the glycolytic process and describe compounds that block the action of those enzymes, inhibiting the growth of cancer cells and and slowing disease progression. This technology is licensed to a local company, Advanced Cancer Therapeutics (ACT).
Found methods of using biomarker levels to diagnose the presence of a kidney disease or the risk of developing such a disease.
Demonstrated the ability of a compound to selectively inhibit cancer cell metabolism and cell growth. This patent has been licensed to a local company, Advanced Cancer Therapeutics (ACT).
Michael Merchant and Jon Klein
Donald Miller, Shelia Thomas,
and Kara Sedoris
(An option is an agreement whereby U of L allows another party (usually a business alliance) limited access to a technology for a limited time in exchange for compensation. The business uses this loan period to determine if it would like to enter into a full license for the intellectual property)
Paula Bates and Tariq Malik, Division of Medical Oncology & Hematology, Gerald Hammond and Bo Xu, College of Arts and Sciences, and Francesca Salipur, student: Option to Kynetic Pharmaceuticals, a startup company, for a cancer therapeutic and diagnostic compound.
Michael Brier, Adam Gaweda, George Aronoff and Alfred Jacobs Jr., Division of Nephrology: Option with Pharos Medicine LLC, a faculty startup, to commercialize a patented software program for medication dosing.
Manicka Vadhanam, Farrukh Aqil and Ramesh Gupta, Division of Medical Oncology & Hematology: Option with 3P Biotechnologies, a faculty startup, to commercialize technology that allows for targeted delivery of cancer therapeutics.
Gerald Dryden, Division of Gastroenterology, Hepatology & Nutrition, John Naber, Guruprasad Giridharan, J.B. Speed School of Engineering, in collaboration with Joseph Vicars: Option agreement with Endoscopy Assist Devices LLC, a local startup, for an endoscopic snare polyp removal device.
Paula Bates, Tariq Malik, Gerald Hammond, Bo Xu, and Francesca Salipur
Manicka Vadhanam, Farrukh Aqil and Ramesh Gupta
Gerald Dryden, John Naber, Guruprasad Giridharan, and Joseph Vicars